The Globe and Mail reports in its Tuesday, Feb. 25, edition that Stifel analyst Justin Keywood continues to rate Andlauer Healthcare Group "buy." The Globe's David Leeder writes in the Eye On Equities column that Mr. Keywood gave his share target a $2 boost to $52. Analysts on average target the shares at $49. Mr. Keywood says in a note: "Our Q4 forecasts are in-line with consensus at $172.2-million revenue, up 2 per cent year-over-year, and $43.2-million adjusted EBITDA (25.1-per-cent margin). We are more focused on the 2025 outlook with growth anticipated to ratchet up to 4- to 7-per-cent organically, along with an M&A update with a balance sheet to support (more than $300-million capacity). Tariffs may also be of focus, but we see no impact." The Globe reported on Nov. 8 that TD Cowen analyst Tim James continued to rank Andlauer "buy." The shares could then be had for $43. The Globe reported on Feb. 4 that RBC analyst Walter Spracklin had reaffirmed his "sector perform" call for Andlauer, which was then worth $46.30. The Globe reported on Feb. 12 that National Bank Financial analyst Cameron Doerksen had reaffirmed his "sector perform" recommendation for Andlauer. The shares were then going for $46.65.